Canadian psychedelics firm MindBio Therapeutics Corp. (CSE: MBIO) on Friday released durability results from its Phase 2A trial for its patented take-home microdose version of lysergic acid diethylamide (LSD), designed to treat depression with “sub-hallucinogenic” doses. The trial found the drug “is a safe and effective drug for treating depression …

The Daily Hit is a recap of the top financial news stories for Wednesday, June 19, 2024. On the Site Massachusetts inspector general: State needs receiver to run cannabis regulatory agency The state’s inspector general found that the commission had been slipping further into dysfunction over the past two years. …

Privately owned psychedelic therapy company Mindbloom announced the positive findings of the largest peer-reviewed study regarding ketamine therapy and psychedelic medicine. The study, published in the Journal of Affective Disorders, was authored by psychiatrists and researchers from Johns Hopkins University School of Medicine, NYU School of Medicine, the Institute for Psycholinguistics and Digital …

IntelGenx Corp. (OTCQB: IGXT) (TSX: IGX) was granted protection under the Companies Creditors Arrangement Act, which is the Canadian version of bankruptcy. The company told investors that on May 27, the court granted an order that approved a sale and investment solicitation process for its assets. The court also approved …